Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 30

1.

Exploratory, Phase II Controlled Trial of Shiunko Ointment Local Application Twice a Day for 4 Weeks in Ethiopian Patients with Localized Cutaneous Leishmaniasis.

Na-Bangchang K, Ahmed O, Hussein J, Hirayama K, Kongjam P, Aseffa A, Karbwang J.

Evid Based Complement Alternat Med. 2016;2016:5984709. doi: 10.1155/2016/5984709. Epub 2016 Apr 19.

2.

A Comparison between the Effects of Glucantime, Topical Trichloroacetic Acid 50% plus Glucantime, and Fractional Carbon Dioxide Laser plus Glucantime on Cutaneous Leishmaniasis Lesions.

Jaffary F, Nilforoushzadeh MA, Siadat A, Haftbaradaran E, Ansari N, Ahmadi E.

Dermatol Res Pract. 2016;2016:6462804. doi: 10.1155/2016/6462804. Epub 2016 Apr 11.

3.

Real-time PCR using FRET technology for Old World cutaneous leishmaniasis species differentiation.

Nath-Chowdhury M, Sangaralingam M, Bastien P, Ravel C, Pratlong F, Mendez J, Libman M, Ndao M.

Parasit Vectors. 2016 May 3;9:255. doi: 10.1186/s13071-016-1531-4.

4.

Treatment of Cutaneous Leishmaniasis Caused by Leishmania aethiopica: A Systematic Review.

van Griensven J, Gadisa E, Aseffa A, Hailu A, Beshah AM, Diro E.

PLoS Negl Trop Dis. 2016 Mar 3;10(3):e0004495. doi: 10.1371/journal.pntd.0004495. eCollection 2016 Mar. Review.

5.

Vector and reservoir control for preventing leishmaniasis.

González U, Pinart M, Sinclair D, Firooz A, Enk C, Vélez ID, Esterhuizen TM, Tristan M, Alvar J.

Cochrane Database Syst Rev. 2015 Aug 5;(8):CD008736. doi: 10.1002/14651858.CD008736.pub2. Review.

6.

Antileishmanial Activity of Disulfiram and Thiuram Disulfide Analogs in an Ex Vivo Model System Is Selectively Enhanced by the Addition of Divalent Metal Ions.

Peniche AG, Renslo AR, Melby PC, Travi BL.

Antimicrob Agents Chemother. 2015 Oct;59(10):6463-70. doi: 10.1128/AAC.05131-14. Epub 2015 Aug 3.

7.

Therapeutic effect of acupuncture in BALB/c model of cutaneous leishmaniasis.

Shakibapour M, Mahmoodi M, Hoseini SG, Rostami F, Mansurian M, Jafari R, Izadi S, Charehdar S, Hejazi SH.

Adv Biomed Res. 2015 Mar 25;4:77. doi: 10.4103/2277-9175.153904. eCollection 2015.

8.

A case of imported Leishmania infantum cutaneous leishmaniasis; an unusual presentation occurring 19 years after travel.

Crowe A, Slavin J, Stark D, Aboltins C.

BMC Infect Dis. 2014 Nov 27;14:597. doi: 10.1186/s12879-014-0597-x.

9.

A randomized controlled phase IIb wound healing trial of cutaneous leishmaniasis ulcers with 0.045% pharmaceutical chlorite (DAC N-055) with and without bipolar high frequency electro-cauterization versus intralesional antimony in Afghanistan.

Stahl HC, Ahmadi F, Schleicher U, Sauerborn R, Bermejo JL, Amirih ML, Sakhayee I, Bogdan C, Stahl KW.

BMC Infect Dis. 2014 Nov 25;14:619. doi: 10.1186/s12879-014-0619-8.

10.

Systematic review of biomarkers to monitor therapeutic response in leishmaniasis.

Kip AE, Balasegaram M, Beijnen JH, Schellens JH, de Vries PJ, Dorlo TP.

Antimicrob Agents Chemother. 2015 Jan;59(1):1-14. doi: 10.1128/AAC.04298-14. Epub 2014 Nov 3. Review.

11.

Current evidence and applications of photodynamic therapy in dermatology.

Wan MT, Lin JY.

Clin Cosmet Investig Dermatol. 2014 May 21;7:145-63. doi: 10.2147/CCID.S35334. eCollection 2014. Review.

12.

Species-directed therapy for leishmaniasis in returning travellers: a comprehensive guide.

Hodiamont CJ, Kager PA, Bart A, de Vries HJ, van Thiel PP, Leenstra T, de Vries PJ, van Vugt M, Grobusch MP, van Gool T.

PLoS Negl Trop Dis. 2014 May 1;8(5):e2832. doi: 10.1371/journal.pntd.0002832. eCollection 2014 May.

13.

Rapid healing of cutaneous leishmaniasis by high-frequency electrocauterization and hydrogel wound care with or without DAC N-055: a randomized controlled phase IIa trial in Kabul.

Jebran AF, Schleicher U, Steiner R, Wentker P, Mahfuz F, Stahl HC, Amin FM, Bogdan C, Stahl KW.

PLoS Negl Trop Dis. 2014 Feb 13;8(2):e2694. doi: 10.1371/journal.pntd.0002694. eCollection 2014 Feb.

14.

The Cochrane Skin Group: a vanguard for developing and promoting evidence-based dermatology.

Reddi A, Prescott L, Doney E, Delamere F, Kollipara R, Dellavalle RP, Williams HC.

J Evid Based Med. 2013 Nov;6(4):236-42. doi: 10.1111/jebm.12068.

15.

Randomized, double-blinded, phase 2 trial of WR 279,396 (paromomycin and gentamicin) for cutaneous leishmaniasis in Panama.

Sosa N, Capitán Z, Nieto J, Nieto M, Calzada J, Paz H, Spadafora C, Kreishman-Deitrick M, Kopydlowski K, Ullman D, McCarthy WF, Ransom J, Berman J, Scott C, Grogl M.

Am J Trop Med Hyg. 2013 Sep;89(3):557-63. doi: 10.4269/ajtmh.12-0736. Epub 2013 Jul 15.

16.

Dressings combined with injection of meglumine antimoniate in the treatment of cutaneous leishmaniasis: a randomized controlled clinical trial.

Khatami A, Talaee R, Rahshenas M, Khamesipour A, Mehryan P, Tehrani S, Dowlati Y, Firooz A.

PLoS One. 2013 Jun 24;8(6):e66123. doi: 10.1371/journal.pone.0066123. Print 2013.

17.

Leishmaniasis: clinical syndromes and treatment.

McGwire BS, Satoskar AR.

QJM. 2014 Jan;107(1):7-14. doi: 10.1093/qjmed/hct116. Epub 2013 Jun 5. Review.

18.

Methodology of clinical trials aimed at assessing interventions for cutaneous leishmaniasis.

Olliaro P, Vaillant M, Arana B, Grogl M, Modabber F, Magill A, Lapujade O, Buffet P, Alvar J.

PLoS Negl Trop Dis. 2013;7(3):e2130. doi: 10.1371/journal.pntd.0002130. Epub 2013 Mar 21.

19.

Triphenylmethane derivatives have high in vitro and in vivo activity against the main causative agents of cutaneous leishmaniasis.

de Souza Pietra RC, Rodrigues LF, Teixeira E, Fried L, Lefkove B, Rabello A, Arbiser J, Ferreira LA, Fernandes AP.

PLoS One. 2013;8(1):e51864. doi: 10.1371/journal.pone.0051864. Epub 2013 Jan 14.

20.

Management of trypanosomiasis and leishmaniasis.

Barrett MP, Croft SL.

Br Med Bull. 2012;104:175-96. doi: 10.1093/bmb/lds031. Epub 2012 Nov 7. Review.

Items per page

Supplemental Content

Write to the Help Desk